iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
iTeos Therapeutics Inc. - TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Adenosine portfolio cl...